Numerous other PI3K inhibitors, including the PI3Kδ inhibitor, INCB050465 (parsaclisib), the dual pan-class I PI3K and mTOR inhibitor, GDC-0084 (paxalisib), and the pan-class I PI3K inhibitor, GDC-0941 (pictilisib), are currently in several phase II and phase III trials, generally in combination with other agents, for a wide range of solid and hematological cancers, including HNSCC, GBM, PIK3CA-mutated breast cancer, renal cell carcinoma (RCC), DLBCL, and mantle cell lymphoma (MCL) (NCT04434937; NCT04774068; NCT03765983; NCT03970447; NCT00996892). Here, MTOR is linked to mantle cell lymphoma.